| Revenue growth | 15% annual growth, 18% Q4 growth. |
|---|---|
| Margins | B2B margins at 14%; group margins 12-13%. |
| Order book | Good pipeline of projects across sales teams. |
| Demand visibility | Robust orders; agro dependent on El Nino. |
| Management confidence | Bullish on 15%+ growth for FY27. |
Growth
FY26 revenue grew 15% to ₹2,396.4cr; Q4 revenue up 18% YoY to ₹684.9cr. EBITDA grew 8% YoY.
Outlook
Guided for minimum 15% revenue growth in FY27; EBITDA margins 12-13%; ₹50-75cr CAPEX; target debt-free in 18 months.
Risks
Geopolitical volatility in Middle East impacting raw material costs (25-30% spikes) and supply chain logistics.
Earnings Call filed with NSE, NSE: ROSSARI. Summary written with AI assistance from the document.
Rossari Biotech Ltd: key numbers
- Share price
- ₹423.00
- Market cap
- ₹2,343 Cr
- Revenue (annual)
- ₹2,396 Cr
- Net profit (annual)
- ₹149.2 Cr
- P/E (TTM)
- 15.6×Sector 37.2×
- Promoter holding
- 68.14%-0.01% QoQ
- FII holding
- 2.03%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Rossari Biotech Ltd
All →Rossari Biotech Investor Presentation: Key Takeaways
Rossari Biotech achieved its highest-ever quarterly revenue of Rs. 697.2 crore and EBITDA of Rs. 80.6 crore in Q1 FY27, driven by 28% YoY top-line growth and international expansion.
- Call
- Guides 15% growth
Rossari Biotech Other Announcement
Rossari Biotech filed its quarterly shareholding pattern for the quarter ended June 30, 2026. The filing notes a change in residential status for a promoter group member.
Rossari Biotech Management Change
Rossari Biotech Limited announced the appointment of Mr. Udeypaul Singh Gill and the re-appointment of Ms. Esha Padmanabhan Achan as Non-Executive Independent Directors.
Rossari Biotech Annual General Meeting
Rossari Biotech Limited held its 17th Annual General Meeting on July 20, 2026. All resolutions proposed in the AGM notice were passed with the requisite majority.
Rossari Biotech Results Update
Rossari Biotech reported Q1 FY27 consolidated revenue of ₹697.2 crore, up 28% YoY. It also established a new 5,000 MTPA greenfield blending facility in Thailand.
Rossari Biotech Earnings Call: Key Takeaways
Rossari Biotech reported record Q1 FY27 revenue of Rs. 697.2 cr (up 28.2% YoY) and EBITDA of Rs. 80.6 cr (up 18.7% YoY), driven by strong demand across core HPPC and TSC segments.